nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—ALB—acquired immunodeficiency syndrome	0.26	1	CbGaD
Sulindac—SLC22A6—Stavudine—acquired immunodeficiency syndrome	0.0906	0.207	CbGbCtD
Sulindac—SLC22A6—Didanosine—acquired immunodeficiency syndrome	0.0687	0.157	CbGbCtD
Sulindac—SLC22A6—Zidovudine—acquired immunodeficiency syndrome	0.0361	0.0825	CbGbCtD
Sulindac—ALB—Saquinavir—acquired immunodeficiency syndrome	0.032	0.0733	CbGbCtD
Sulindac—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0307	0.0703	CbGbCtD
Sulindac—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0298	0.068	CbGbCtD
Sulindac—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.028	0.064	CbGbCtD
Sulindac—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.028	0.064	CbGbCtD
Sulindac—SLC22A6—Lamivudine—acquired immunodeficiency syndrome	0.0279	0.0638	CbGbCtD
Sulindac—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0253	0.0578	CbGbCtD
Sulindac—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0212	0.0485	CbGbCtD
Sulindac—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0192	0.0438	CbGbCtD
Sulindac—AKR1B1—blood plasma—acquired immunodeficiency syndrome	0.00416	0.0602	CbGeAlD
Sulindac—MAPK3—endothelium—acquired immunodeficiency syndrome	0.0034	0.0491	CbGeAlD
Sulindac—MAPK3—blood plasma—acquired immunodeficiency syndrome	0.00302	0.0436	CbGeAlD
Sulindac—PTGDR2—blood—acquired immunodeficiency syndrome	0.00287	0.0415	CbGeAlD
Sulindac—AKR1B1—retina—acquired immunodeficiency syndrome	0.00228	0.0329	CbGeAlD
Sulindac—PTGDR2—brain—acquired immunodeficiency syndrome	0.00178	0.0257	CbGeAlD
Sulindac—MAPK3—retina—acquired immunodeficiency syndrome	0.00165	0.0239	CbGeAlD
Sulindac—AKR1B1—lymphoid tissue—acquired immunodeficiency syndrome	0.00162	0.0234	CbGeAlD
Sulindac—AKR1B1—digestive system—acquired immunodeficiency syndrome	0.0016	0.0231	CbGeAlD
Sulindac—AKR1B1—blood—acquired immunodeficiency syndrome	0.00153	0.022	CbGeAlD
Sulindac—AKR1B1—bone marrow—acquired immunodeficiency syndrome	0.00148	0.0213	CbGeAlD
Sulindac—AKR1B1—spinal cord—acquired immunodeficiency syndrome	0.00147	0.0212	CbGeAlD
Sulindac—MAPK3—skin of body—acquired immunodeficiency syndrome	0.00145	0.021	CbGeAlD
Sulindac—AKR1B1—vagina—acquired immunodeficiency syndrome	0.00141	0.0204	CbGeAlD
Sulindac—AKR1B1—lung—acquired immunodeficiency syndrome	0.00134	0.0193	CbGeAlD
Sulindac—PPARD—lymphoid tissue—acquired immunodeficiency syndrome	0.00128	0.0184	CbGeAlD
Sulindac—PPARD—digestive system—acquired immunodeficiency syndrome	0.00126	0.0182	CbGeAlD
Sulindac—AKR1B1—nervous system—acquired immunodeficiency syndrome	0.00124	0.0179	CbGeAlD
Sulindac—AKR1B1—central nervous system—acquired immunodeficiency syndrome	0.00119	0.0172	CbGeAlD
Sulindac—MAPK3—lymphoid tissue—acquired immunodeficiency syndrome	0.00118	0.017	CbGeAlD
Sulindac—MAPK3—digestive system—acquired immunodeficiency syndrome	0.00116	0.0168	CbGeAlD
Sulindac—PPARD—vagina—acquired immunodeficiency syndrome	0.00111	0.0161	CbGeAlD
Sulindac—MAPK3—blood—acquired immunodeficiency syndrome	0.00111	0.016	CbGeAlD
Sulindac—MAPK3—bone marrow—acquired immunodeficiency syndrome	0.00107	0.0155	CbGeAlD
Sulindac—MAPK3—spinal cord—acquired immunodeficiency syndrome	0.00107	0.0154	CbGeAlD
Sulindac—PPARD—lung—acquired immunodeficiency syndrome	0.00105	0.0152	CbGeAlD
Sulindac—MAPK3—vagina—acquired immunodeficiency syndrome	0.00103	0.0148	CbGeAlD
Sulindac—PPARD—nervous system—acquired immunodeficiency syndrome	0.000974	0.0141	CbGeAlD
Sulindac—MAPK3—lung—acquired immunodeficiency syndrome	0.00097	0.014	CbGeAlD
Sulindac—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000947	0.0137	CbGeAlD
Sulindac—AKR1B1—brain—acquired immunodeficiency syndrome	0.000947	0.0137	CbGeAlD
Sulindac—PPARD—central nervous system—acquired immunodeficiency syndrome	0.000938	0.0135	CbGeAlD
Sulindac—PTGS1—endothelium—acquired immunodeficiency syndrome	0.000924	0.0133	CbGeAlD
Sulindac—AKR1B1—lymph node—acquired immunodeficiency syndrome	0.000915	0.0132	CbGeAlD
Sulindac—MAPK3—nervous system—acquired immunodeficiency syndrome	0.000898	0.013	CbGeAlD
Sulindac—PTGS2—endothelium—acquired immunodeficiency syndrome	0.000883	0.0128	CbGeAlD
Sulindac—MAPK3—central nervous system—acquired immunodeficiency syndrome	0.000864	0.0125	CbGeAlD
Sulindac—PTGS1—blood plasma—acquired immunodeficiency syndrome	0.00082	0.0119	CbGeAlD
Sulindac—PTGS2—blood plasma—acquired immunodeficiency syndrome	0.000784	0.0113	CbGeAlD
Sulindac—PPARD—brain—acquired immunodeficiency syndrome	0.000745	0.0108	CbGeAlD
Sulindac—PPARD—lymph node—acquired immunodeficiency syndrome	0.000719	0.0104	CbGeAlD
Sulindac—MAPK3—brain—acquired immunodeficiency syndrome	0.000686	0.00991	CbGeAlD
Sulindac—MAPK3—lymph node—acquired immunodeficiency syndrome	0.000663	0.00958	CbGeAlD
Sulindac—SLC22A6—brain—acquired immunodeficiency syndrome	0.000525	0.00758	CbGeAlD
Sulindac—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000449	0.00649	CbGeAlD
Sulindac—PTGS1—skin of body—acquired immunodeficiency syndrome	0.000394	0.0057	CbGeAlD
Sulindac—PTGS2—skin of body—acquired immunodeficiency syndrome	0.000377	0.00545	CbGeAlD
Sulindac—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000364	0.00526	CbGeAlD
Sulindac—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000359	0.00519	CbGeAlD
Sulindac—CYP1A2—blood—acquired immunodeficiency syndrome	0.000347	0.00501	CbGeAlD
Sulindac—CYP1A1—blood—acquired immunodeficiency syndrome	0.000342	0.00494	CbGeAlD
Sulindac—ALB—brain—acquired immunodeficiency syndrome	0.000327	0.00473	CbGeAlD
Sulindac—CYP1A1—vagina—acquired immunodeficiency syndrome	0.000317	0.00458	CbGeAlD
Sulindac—ALB—lymph node—acquired immunodeficiency syndrome	0.000316	0.00457	CbGeAlD
Sulindac—PTGS1—digestive system—acquired immunodeficiency syndrome	0.000316	0.00456	CbGeAlD
Sulindac—PTGS2—lymphoid tissue—acquired immunodeficiency syndrome	0.000305	0.00441	CbGeAlD
Sulindac—CYP1A2—lung—acquired immunodeficiency syndrome	0.000304	0.00439	CbGeAlD
Sulindac—PTGS2—digestive system—acquired immunodeficiency syndrome	0.000302	0.00436	CbGeAlD
Sulindac—PTGS1—blood—acquired immunodeficiency syndrome	0.000301	0.00434	CbGeAlD
Sulindac—CYP1A1—lung—acquired immunodeficiency syndrome	0.0003	0.00433	CbGeAlD
Sulindac—PTGS1—spinal cord—acquired immunodeficiency syndrome	0.00029	0.00418	CbGeAlD
Sulindac—PTGS2—blood—acquired immunodeficiency syndrome	0.000287	0.00415	CbGeAlD
Sulindac—PTGS1—vagina—acquired immunodeficiency syndrome	0.000279	0.00402	CbGeAlD
Sulindac—PTGS2—bone marrow—acquired immunodeficiency syndrome	0.000278	0.00402	CbGeAlD
Sulindac—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.000278	0.00401	CbGeAlD
Sulindac—PTGS2—spinal cord—acquired immunodeficiency syndrome	0.000277	0.004	CbGeAlD
Sulindac—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.000267	0.00386	CbGeAlD
Sulindac—PTGS2—vagina—acquired immunodeficiency syndrome	0.000266	0.00385	CbGeAlD
Sulindac—PTGS1—lung—acquired immunodeficiency syndrome	0.000263	0.00381	CbGeAlD
Sulindac—PTGS2—lung—acquired immunodeficiency syndrome	0.000252	0.00364	CbGeAlD
Sulindac—PTGS1—nervous system—acquired immunodeficiency syndrome	0.000244	0.00352	CbGeAlD
Sulindac—PTGS1—central nervous system—acquired immunodeficiency syndrome	0.000235	0.00339	CbGeAlD
Sulindac—PTGS2—nervous system—acquired immunodeficiency syndrome	0.000233	0.00337	CbGeAlD
Sulindac—PTGS2—central nervous system—acquired immunodeficiency syndrome	0.000225	0.00324	CbGeAlD
Sulindac—CYP1A1—brain—acquired immunodeficiency syndrome	0.000212	0.00307	CbGeAlD
Sulindac—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.000205	0.00296	CbGeAlD
Sulindac—PTGS1—brain—acquired immunodeficiency syndrome	0.000187	0.00269	CbGeAlD
Sulindac—PTGS1—lymph node—acquired immunodeficiency syndrome	0.00018	0.0026	CbGeAlD
Sulindac—PTGS2—brain—acquired immunodeficiency syndrome	0.000178	0.00258	CbGeAlD
Sulindac—PTGS2—lymph node—acquired immunodeficiency syndrome	0.000172	0.00249	CbGeAlD
Sulindac—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000144	0.000783	CcSEcCtD
Sulindac—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000144	0.000782	CcSEcCtD
Sulindac—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000144	0.000782	CcSEcCtD
Sulindac—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000144	0.000781	CcSEcCtD
Sulindac—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000144	0.000781	CcSEcCtD
Sulindac—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000143	0.000778	CcSEcCtD
Sulindac—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000143	0.000777	CcSEcCtD
Sulindac—Rash—Didanosine—acquired immunodeficiency syndrome	0.000143	0.000776	CcSEcCtD
Sulindac—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000143	0.000775	CcSEcCtD
Sulindac—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000143	0.000775	CcSEcCtD
Sulindac—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000143	0.000775	CcSEcCtD
Sulindac—Headache—Didanosine—acquired immunodeficiency syndrome	0.000142	0.000771	CcSEcCtD
Sulindac—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000142	0.00077	CcSEcCtD
Sulindac—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000142	0.000769	CcSEcCtD
Sulindac—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000142	0.000768	CcSEcCtD
Sulindac—Malaise—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.000768	CcSEcCtD
Sulindac—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000141	0.000768	CcSEcCtD
Sulindac—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000141	0.000767	CcSEcCtD
Sulindac—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000141	0.000766	CcSEcCtD
Sulindac—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000141	0.000765	CcSEcCtD
Sulindac—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.000765	CcSEcCtD
Sulindac—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000141	0.000764	CcSEcCtD
Sulindac—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000141	0.000764	CcSEcCtD
Sulindac—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.000764	CcSEcCtD
Sulindac—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.00014	0.000762	CcSEcCtD
Sulindac—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.00014	0.000762	CcSEcCtD
Sulindac—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.00014	0.00076	CcSEcCtD
Sulindac—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.00014	0.000759	CcSEcCtD
Sulindac—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00014	0.000758	CcSEcCtD
Sulindac—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00014	0.000757	CcSEcCtD
Sulindac—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000139	0.000756	CcSEcCtD
Sulindac—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000139	0.000755	CcSEcCtD
Sulindac—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000139	0.000755	CcSEcCtD
Sulindac—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000139	0.000754	CcSEcCtD
Sulindac—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000139	0.000753	CcSEcCtD
Sulindac—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000139	0.000753	CcSEcCtD
Sulindac—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000139	0.000753	CcSEcCtD
Sulindac—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000138	0.000751	CcSEcCtD
Sulindac—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000138	0.000751	CcSEcCtD
Sulindac—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000138	0.000748	CcSEcCtD
Sulindac—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000137	0.000745	CcSEcCtD
Sulindac—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000137	0.000745	CcSEcCtD
Sulindac—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000137	0.000744	CcSEcCtD
Sulindac—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000137	0.000744	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000137	0.000743	CcSEcCtD
Sulindac—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000137	0.000742	CcSEcCtD
Sulindac—MAPK3—VEGFR2 mediated cell proliferation—IL6—acquired immunodeficiency syndrome	0.000136	0.00277	CbGpPWpGaD
Sulindac—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000136	0.000739	CcSEcCtD
Sulindac—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000136	0.000738	CcSEcCtD
Sulindac—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000136	0.000738	CcSEcCtD
Sulindac—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000136	0.000738	CcSEcCtD
Sulindac—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000135	0.000735	CcSEcCtD
Sulindac—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000135	0.000734	CcSEcCtD
Sulindac—PTGDR2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000135	0.00275	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000135	0.00275	CbGpPWpGaD
Sulindac—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000135	0.000733	CcSEcCtD
Sulindac—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000135	0.000733	CcSEcCtD
Sulindac—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000135	0.000732	CcSEcCtD
Sulindac—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000135	0.000731	CcSEcCtD
Sulindac—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000135	0.000731	CcSEcCtD
Sulindac—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000134	0.00073	CcSEcCtD
Sulindac—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000134	0.00073	CcSEcCtD
Sulindac—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000134	0.000728	CcSEcCtD
Sulindac—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000134	0.000727	CcSEcCtD
Sulindac—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000134	0.000727	CcSEcCtD
Sulindac—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000134	0.000725	CcSEcCtD
Sulindac—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000134	0.000725	CcSEcCtD
Sulindac—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000134	0.000725	CcSEcCtD
Sulindac—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000134	0.000725	CcSEcCtD
Sulindac—MAPK3—Regulation of Telomerase—IL2—acquired immunodeficiency syndrome	0.000133	0.00271	CbGpPWpGaD
Sulindac—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000133	0.000722	CcSEcCtD
Sulindac—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000133	0.00072	CcSEcCtD
Sulindac—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000132	0.000718	CcSEcCtD
Sulindac—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000132	0.000716	CcSEcCtD
Sulindac—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000132	0.000714	CcSEcCtD
Sulindac—PPARD—Gene Expression—CCNT1—acquired immunodeficiency syndrome	0.000131	0.00267	CbGpPWpGaD
Sulindac—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000131	0.000712	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000131	0.000711	CcSEcCtD
Sulindac—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000131	0.00071	CcSEcCtD
Sulindac—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000131	0.000709	CcSEcCtD
Sulindac—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000131	0.000709	CcSEcCtD
Sulindac—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.00013	0.000707	CcSEcCtD
Sulindac—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00013	0.000707	CcSEcCtD
Sulindac—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.00013	0.000706	CcSEcCtD
Sulindac—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.00013	0.000706	CcSEcCtD
Sulindac—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.00013	0.000705	CcSEcCtD
Sulindac—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.00013	0.000704	CcSEcCtD
Sulindac—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00013	0.000704	CcSEcCtD
Sulindac—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.00013	0.000703	CcSEcCtD
Sulindac—PTGS2—Overview of nanoparticle effects—IL6—acquired immunodeficiency syndrome	0.000129	0.00263	CbGpPWpGaD
Sulindac—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000129	0.000701	CcSEcCtD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—IFNG—acquired immunodeficiency syndrome	0.000129	0.00262	CbGpPWpGaD
Sulindac—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000129	0.000698	CcSEcCtD
Sulindac—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000129	0.000698	CcSEcCtD
Sulindac—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000129	0.000698	CcSEcCtD
Sulindac—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000128	0.000697	CcSEcCtD
Sulindac—MAPK3—Ceramide signaling pathway—TNF—acquired immunodeficiency syndrome	0.000128	0.00261	CbGpPWpGaD
Sulindac—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000128	0.000696	CcSEcCtD
Sulindac—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000128	0.000696	CcSEcCtD
Sulindac—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000128	0.000695	CcSEcCtD
Sulindac—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000128	0.000694	CcSEcCtD
Sulindac—PPARD—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000128	0.0026	CbGpPWpGaD
Sulindac—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000128	0.000693	CcSEcCtD
Sulindac—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000127	0.000692	CcSEcCtD
Sulindac—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000127	0.000692	CcSEcCtD
Sulindac—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000127	0.000692	CcSEcCtD
Sulindac—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000127	0.000688	CcSEcCtD
Sulindac—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000127	0.000687	CcSEcCtD
Sulindac—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000126	0.000686	CcSEcCtD
Sulindac—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000126	0.000684	CcSEcCtD
Sulindac—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000126	0.000683	CcSEcCtD
Sulindac—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000126	0.000683	CcSEcCtD
Sulindac—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000126	0.000681	CcSEcCtD
Sulindac—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000125	0.00068	CcSEcCtD
Sulindac—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000125	0.000679	CcSEcCtD
Sulindac—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000125	0.000679	CcSEcCtD
Sulindac—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000125	0.000676	CcSEcCtD
Sulindac—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000124	0.000675	CcSEcCtD
Sulindac—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000124	0.000675	CcSEcCtD
Sulindac—MAPK3—Angiopoietin receptor Tie2-mediated signaling—TNF—acquired immunodeficiency syndrome	0.000124	0.00252	CbGpPWpGaD
Sulindac—Rash—Stavudine—acquired immunodeficiency syndrome	0.000124	0.000674	CcSEcCtD
Sulindac—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000124	0.000673	CcSEcCtD
Sulindac—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000124	0.000673	CcSEcCtD
Sulindac—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000124	0.000672	CcSEcCtD
Sulindac—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000124	0.000672	CcSEcCtD
Sulindac—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000124	0.000671	CcSEcCtD
Sulindac—Headache—Stavudine—acquired immunodeficiency syndrome	0.000123	0.000669	CcSEcCtD
Sulindac—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000123	0.000669	CcSEcCtD
Sulindac—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000123	0.000668	CcSEcCtD
Sulindac—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000123	0.000667	CcSEcCtD
Sulindac—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000123	0.000666	CcSEcCtD
Sulindac—Rash—Abacavir—acquired immunodeficiency syndrome	0.000122	0.000664	CcSEcCtD
Sulindac—ALB—Folate Metabolism—IL4—acquired immunodeficiency syndrome	0.000122	0.00248	CbGpPWpGaD
Sulindac—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000122	0.000663	CcSEcCtD
Sulindac—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000122	0.000663	CcSEcCtD
Sulindac—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000122	0.000663	CcSEcCtD
Sulindac—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000122	0.000662	CcSEcCtD
Sulindac—MAPK3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000122	0.00248	CbGpPWpGaD
Sulindac—Headache—Abacavir—acquired immunodeficiency syndrome	0.000122	0.000659	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000121	0.000658	CcSEcCtD
Sulindac—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000121	0.000657	CcSEcCtD
Sulindac—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000121	0.000657	CcSEcCtD
Sulindac—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.00012	0.000653	CcSEcCtD
Sulindac—Shock—Lamivudine—acquired immunodeficiency syndrome	0.00012	0.000652	CcSEcCtD
Sulindac—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.00012	0.000649	CcSEcCtD
Sulindac—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.00012	0.000649	CcSEcCtD
Sulindac—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.000648	CcSEcCtD
Sulindac—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000119	0.000648	CcSEcCtD
Sulindac—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000119	0.000645	CcSEcCtD
Sulindac—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.000644	CcSEcCtD
Sulindac—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000119	0.000643	CcSEcCtD
Sulindac—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000118	0.000642	CcSEcCtD
Sulindac—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000118	0.000641	CcSEcCtD
Sulindac—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000118	0.000638	CcSEcCtD
Sulindac—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000117	0.000637	CcSEcCtD
Sulindac—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000117	0.000636	CcSEcCtD
Sulindac—MAPK3—Interferon Signaling—HLA-B—acquired immunodeficiency syndrome	0.000117	0.00238	CbGpPWpGaD
Sulindac—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000117	0.000636	CcSEcCtD
Sulindac—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000117	0.000635	CcSEcCtD
Sulindac—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000117	0.000635	CcSEcCtD
Sulindac—MAPK3—TGF-beta Receptor Signaling—TNF—acquired immunodeficiency syndrome	0.000117	0.00237	CbGpPWpGaD
Sulindac—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000117	0.000633	CcSEcCtD
Sulindac—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000116	0.000632	CcSEcCtD
Sulindac—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000116	0.000628	CcSEcCtD
Sulindac—MAPK3—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.000116	0.00235	CbGpPWpGaD
Sulindac—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000116	0.000628	CcSEcCtD
Sulindac—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000115	0.000625	CcSEcCtD
Sulindac—MAPK3—TWEAK Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000115	0.00234	CbGpPWpGaD
Sulindac—MAPK3—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	0.000115	0.00234	CbGpPWpGaD
Sulindac—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.000624	CcSEcCtD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—IL2—acquired immunodeficiency syndrome	0.000115	0.00233	CbGpPWpGaD
Sulindac—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000115	0.000622	CcSEcCtD
Sulindac—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000114	0.00062	CcSEcCtD
Sulindac—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000114	0.00062	CcSEcCtD
Sulindac—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000114	0.00062	CcSEcCtD
Sulindac—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000114	0.000619	CcSEcCtD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—acquired immunodeficiency syndrome	0.000114	0.00232	CbGpPWpGaD
Sulindac—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000114	0.000618	CcSEcCtD
Sulindac—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000114	0.000617	CcSEcCtD
Sulindac—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000114	0.000617	CcSEcCtD
Sulindac—MAPK3—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	0.000114	0.00231	CbGpPWpGaD
Sulindac—PPARD—Adipogenesis—TNF—acquired immunodeficiency syndrome	0.000113	0.0023	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000113	0.0023	CbGpPWpGaD
Sulindac—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000113	0.000614	CcSEcCtD
Sulindac—MAPK3—FCERI mediated MAPK activation—IL6—acquired immunodeficiency syndrome	0.000113	0.0023	CbGpPWpGaD
Sulindac—MAPK3—IL-6 signaling pathway—IL6—acquired immunodeficiency syndrome	0.000113	0.0023	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—HLA-B—acquired immunodeficiency syndrome	0.000113	0.00229	CbGpPWpGaD
Sulindac—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000113	0.000612	CcSEcCtD
Sulindac—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000113	0.000611	CcSEcCtD
Sulindac—PTGDR2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000112	0.00227	CbGpPWpGaD
Sulindac—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000111	0.000604	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000111	0.000604	CcSEcCtD
Sulindac—MAPK3—FRS2-mediated cascade—IL6—acquired immunodeficiency syndrome	0.000111	0.00225	CbGpPWpGaD
Sulindac—MAPK3—Signalling to ERKs—IL6—acquired immunodeficiency syndrome	0.000111	0.00225	CbGpPWpGaD
Sulindac—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000111	0.000601	CcSEcCtD
Sulindac—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.0006	CcSEcCtD
Sulindac—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.00011	0.000599	CcSEcCtD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.00011	0.00223	CbGpPWpGaD
Sulindac—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.000595	CcSEcCtD
Sulindac—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.000595	CcSEcCtD
Sulindac—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.00011	0.000594	CcSEcCtD
Sulindac—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.000591	CcSEcCtD
Sulindac—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000109	0.000591	CcSEcCtD
Sulindac—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000109	0.00059	CcSEcCtD
Sulindac—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.00059	CcSEcCtD
Sulindac—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.000589	CcSEcCtD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	0.000108	0.0022	CbGpPWpGaD
Sulindac—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000108	0.000586	CcSEcCtD
Sulindac—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.000585	CcSEcCtD
Sulindac—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000108	0.000585	CcSEcCtD
Sulindac—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.000584	CcSEcCtD
Sulindac—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000107	0.000582	CcSEcCtD
Sulindac—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000106	0.000577	CcSEcCtD
Sulindac—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000106	0.000576	CcSEcCtD
Sulindac—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000106	0.000575	CcSEcCtD
Sulindac—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000574	CcSEcCtD
Sulindac—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000573	CcSEcCtD
Sulindac—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000105	0.000572	CcSEcCtD
Sulindac—MAPK3—TSLP Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000105	0.00214	CbGpPWpGaD
Sulindac—MAPK3—Interleukin-2 signaling—IL6—acquired immunodeficiency syndrome	0.000105	0.00214	CbGpPWpGaD
Sulindac—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000105	0.000571	CcSEcCtD
Sulindac—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.000571	CcSEcCtD
Sulindac—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000568	CcSEcCtD
Sulindac—MAPK3—Corticotropin-releasing hormone—IL2—acquired immunodeficiency syndrome	0.000105	0.00213	CbGpPWpGaD
Sulindac—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000567	CcSEcCtD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IFNA1—acquired immunodeficiency syndrome	0.000104	0.00211	CbGpPWpGaD
Sulindac—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.00056	CcSEcCtD
Sulindac—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.000558	CcSEcCtD
Sulindac—PTGDR2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000103	0.00209	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000102	0.00207	CbGpPWpGaD
Sulindac—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000552	CcSEcCtD
Sulindac—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000552	CcSEcCtD
Sulindac—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000102	0.000552	CcSEcCtD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—acquired immunodeficiency syndrome	0.000101	0.00206	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000101	0.00206	CbGpPWpGaD
Sulindac—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.000549	CcSEcCtD
Sulindac—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000101	0.000549	CcSEcCtD
Sulindac—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000546	CcSEcCtD
Sulindac—MAPK3—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	0.0001	0.00204	CbGpPWpGaD
Sulindac—Rash—Indinavir—acquired immunodeficiency syndrome	0.0001	0.000545	CcSEcCtD
Sulindac—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.0001	0.000544	CcSEcCtD
Sulindac—PTGS1—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	0.0001	0.00204	CbGpPWpGaD
Sulindac—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	9.99e-05	0.000542	CcSEcCtD
Sulindac—Headache—Indinavir—acquired immunodeficiency syndrome	9.97e-05	0.000541	CcSEcCtD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—TNF—acquired immunodeficiency syndrome	9.94e-05	0.00202	CbGpPWpGaD
Sulindac—Dizziness—Efavirenz—acquired immunodeficiency syndrome	9.94e-05	0.00054	CcSEcCtD
Sulindac—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	9.84e-05	0.000534	CcSEcCtD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	9.82e-05	0.002	CbGpPWpGaD
Sulindac—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	9.8e-05	0.000532	CcSEcCtD
Sulindac—Urticaria—Lamivudine—acquired immunodeficiency syndrome	9.7e-05	0.000527	CcSEcCtD
Sulindac—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	9.66e-05	0.000524	CcSEcCtD
Sulindac—MAPK3—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	9.65e-05	0.00196	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	9.62e-05	0.00195	CbGpPWpGaD
Sulindac—Vomiting—Efavirenz—acquired immunodeficiency syndrome	9.56e-05	0.000519	CcSEcCtD
Sulindac—Asthenia—Ritonavir—acquired immunodeficiency syndrome	9.55e-05	0.000518	CcSEcCtD
Sulindac—Dizziness—Delavirdine—acquired immunodeficiency syndrome	9.51e-05	0.000516	CcSEcCtD
Sulindac—PTGS2—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	9.5e-05	0.00193	CbGpPWpGaD
Sulindac—Rash—Efavirenz—acquired immunodeficiency syndrome	9.48e-05	0.000514	CcSEcCtD
Sulindac—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	9.47e-05	0.000514	CcSEcCtD
Sulindac—Nausea—Indinavir—acquired immunodeficiency syndrome	9.45e-05	0.000513	CcSEcCtD
Sulindac—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	9.43e-05	0.000512	CcSEcCtD
Sulindac—Headache—Efavirenz—acquired immunodeficiency syndrome	9.42e-05	0.000511	CcSEcCtD
Sulindac—Pruritus—Ritonavir—acquired immunodeficiency syndrome	9.41e-05	0.000511	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.39e-05	0.00191	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.26e-05	0.00188	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—IL2—acquired immunodeficiency syndrome	9.21e-05	0.00187	CbGpPWpGaD
Sulindac—Asthenia—Saquinavir—acquired immunodeficiency syndrome	9.19e-05	0.000499	CcSEcCtD
Sulindac—MAPK3—MAP kinase activation in TLR cascade—IL6—acquired immunodeficiency syndrome	9.15e-05	0.00186	CbGpPWpGaD
Sulindac—Vomiting—Delavirdine—acquired immunodeficiency syndrome	9.15e-05	0.000496	CcSEcCtD
Sulindac—PTGS1—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	9.14e-05	0.00186	CbGpPWpGaD
Sulindac—PPARD—Adipogenesis—IL6—acquired immunodeficiency syndrome	9.14e-05	0.00186	CbGpPWpGaD
Sulindac—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	9.1e-05	0.000494	CcSEcCtD
Sulindac—ALB—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	9.09e-05	0.00185	CbGpPWpGaD
Sulindac—Rash—Delavirdine—acquired immunodeficiency syndrome	9.07e-05	0.000492	CcSEcCtD
Sulindac—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	9.06e-05	0.000492	CcSEcCtD
Sulindac—Pruritus—Saquinavir—acquired immunodeficiency syndrome	9.06e-05	0.000492	CcSEcCtD
Sulindac—Headache—Delavirdine—acquired immunodeficiency syndrome	9.01e-05	0.000489	CcSEcCtD
Sulindac—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	9e-05	0.000488	CcSEcCtD
Sulindac—Nausea—Efavirenz—acquired immunodeficiency syndrome	8.93e-05	0.000485	CcSEcCtD
Sulindac—Dizziness—Ritonavir—acquired immunodeficiency syndrome	8.8e-05	0.000477	CcSEcCtD
Sulindac—MAPK3—ATF-2 transcription factor network—IL6—acquired immunodeficiency syndrome	8.78e-05	0.00178	CbGpPWpGaD
Sulindac—Asthenia—Lamivudine—acquired immunodeficiency syndrome	8.76e-05	0.000476	CcSEcCtD
Sulindac—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	8.76e-05	0.000475	CcSEcCtD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	8.71e-05	0.00177	CbGpPWpGaD
Sulindac—Pruritus—Lamivudine—acquired immunodeficiency syndrome	8.64e-05	0.000469	CcSEcCtD
Sulindac—MAPK3—Alzheimers Disease—TNF—acquired immunodeficiency syndrome	8.61e-05	0.00175	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	8.58e-05	0.00174	CbGpPWpGaD
Sulindac—Nausea—Delavirdine—acquired immunodeficiency syndrome	8.55e-05	0.000464	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.49e-05	0.00172	CbGpPWpGaD
Sulindac—Dizziness—Saquinavir—acquired immunodeficiency syndrome	8.47e-05	0.00046	CcSEcCtD
Sulindac—Vomiting—Ritonavir—acquired immunodeficiency syndrome	8.46e-05	0.000459	CcSEcCtD
Sulindac—Rash—Ritonavir—acquired immunodeficiency syndrome	8.39e-05	0.000455	CcSEcCtD
Sulindac—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	8.38e-05	0.000455	CcSEcCtD
Sulindac—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	8.36e-05	0.000454	CcSEcCtD
Sulindac—Headache—Ritonavir—acquired immunodeficiency syndrome	8.33e-05	0.000452	CcSEcCtD
Sulindac—MAPK3—Innate Immune System—MBL2—acquired immunodeficiency syndrome	8.25e-05	0.00168	CbGpPWpGaD
Sulindac—MAPK3—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	8.2e-05	0.00167	CbGpPWpGaD
Sulindac—Vomiting—Saquinavir—acquired immunodeficiency syndrome	8.14e-05	0.000442	CcSEcCtD
Sulindac—MAPK3—Cytokine Signaling in Immune system—CSF2—acquired immunodeficiency syndrome	8.13e-05	0.00165	CbGpPWpGaD
Sulindac—Dizziness—Lamivudine—acquired immunodeficiency syndrome	8.08e-05	0.000438	CcSEcCtD
Sulindac—Rash—Saquinavir—acquired immunodeficiency syndrome	8.07e-05	0.000438	CcSEcCtD
Sulindac—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	8.07e-05	0.000438	CcSEcCtD
Sulindac—Headache—Saquinavir—acquired immunodeficiency syndrome	8.02e-05	0.000435	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.98e-05	0.00162	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.98e-05	0.00162	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	7.95e-05	0.00162	CbGpPWpGaD
Sulindac—Nausea—Ritonavir—acquired immunodeficiency syndrome	7.9e-05	0.000429	CcSEcCtD
Sulindac—PTGS2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	7.89e-05	0.0016	CbGpPWpGaD
Sulindac—MAPK3—NCAM signaling for neurite out-growth—IL6—acquired immunodeficiency syndrome	7.84e-05	0.00159	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-B—acquired immunodeficiency syndrome	7.82e-05	0.00159	CbGpPWpGaD
Sulindac—Vomiting—Lamivudine—acquired immunodeficiency syndrome	7.77e-05	0.000421	CcSEcCtD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	7.73e-05	0.00157	CbGpPWpGaD
Sulindac—Rash—Lamivudine—acquired immunodeficiency syndrome	7.7e-05	0.000418	CcSEcCtD
Sulindac—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	7.7e-05	0.000418	CcSEcCtD
Sulindac—Headache—Lamivudine—acquired immunodeficiency syndrome	7.65e-05	0.000415	CcSEcCtD
Sulindac—MAPK3—TNF alpha Signaling Pathway—TNF—acquired immunodeficiency syndrome	7.62e-05	0.00155	CbGpPWpGaD
Sulindac—Nausea—Saquinavir—acquired immunodeficiency syndrome	7.61e-05	0.000413	CcSEcCtD
Sulindac—ALB—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	7.39e-05	0.0015	CbGpPWpGaD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—acquired immunodeficiency syndrome	7.38e-05	0.0015	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.38e-05	0.0015	CbGpPWpGaD
Sulindac—MAPK3—Disease—APOBEC3G—acquired immunodeficiency syndrome	7.32e-05	0.00149	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—CD4—acquired immunodeficiency syndrome	7.28e-05	0.00148	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	7.26e-05	0.00147	CbGpPWpGaD
Sulindac—Nausea—Lamivudine—acquired immunodeficiency syndrome	7.26e-05	0.000394	CcSEcCtD
Sulindac—MAPK3—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—acquired immunodeficiency syndrome	7.24e-05	0.00147	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—IFNG—acquired immunodeficiency syndrome	7.24e-05	0.00147	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—ALB—acquired immunodeficiency syndrome	7.24e-05	0.00147	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.2e-05	0.00146	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	7.05e-05	0.00143	CbGpPWpGaD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—TNF—acquired immunodeficiency syndrome	7.02e-05	0.00143	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	7.01e-05	0.00142	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	7.01e-05	0.00142	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	6.9e-05	0.0014	CbGpPWpGaD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—IL6—acquired immunodeficiency syndrome	6.75e-05	0.00137	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—CCNT1—acquired immunodeficiency syndrome	6.71e-05	0.00136	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.68e-05	0.00136	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—IL2—acquired immunodeficiency syndrome	6.57e-05	0.00133	CbGpPWpGaD
Sulindac—MAPK3—MyD88 cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	6.55e-05	0.00133	CbGpPWpGaD
Sulindac—MAPK3—IRS-mediated signalling—IL6—acquired immunodeficiency syndrome	6.55e-05	0.00133	CbGpPWpGaD
Sulindac—MAPK3—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—acquired immunodeficiency syndrome	6.49e-05	0.00132	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—IFNA1—acquired immunodeficiency syndrome	6.47e-05	0.00131	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CCR2—acquired immunodeficiency syndrome	6.47e-05	0.00131	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	6.4e-05	0.0013	CbGpPWpGaD
Sulindac—MAPK3—IRS-related events—IL6—acquired immunodeficiency syndrome	6.37e-05	0.00129	CbGpPWpGaD
Sulindac—MAPK3—MyD88 dependent cascade initiated on endosome—IL6—acquired immunodeficiency syndrome	6.37e-05	0.00129	CbGpPWpGaD
Sulindac—MAPK3—IRS-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	6.32e-05	0.00128	CbGpPWpGaD
Sulindac—MAPK3—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	6.26e-05	0.00127	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	6.25e-05	0.00127	CbGpPWpGaD
Sulindac—MAPK3—Disease—CCNT1—acquired immunodeficiency syndrome	6.23e-05	0.00127	CbGpPWpGaD
Sulindac—MAPK3—Toll Like Receptor 9 (TLR9) Cascade—IL6—acquired immunodeficiency syndrome	6.15e-05	0.00125	CbGpPWpGaD
Sulindac—MAPK3—Insulin receptor signalling cascade—IL6—acquired immunodeficiency syndrome	6.15e-05	0.00125	CbGpPWpGaD
Sulindac—MAPK3—TNF alpha Signaling Pathway—IL6—acquired immunodeficiency syndrome	6.15e-05	0.00125	CbGpPWpGaD
Sulindac—MAPK3—IGF1R signaling cascade—IL6—acquired immunodeficiency syndrome	6.15e-05	0.00125	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	6.13e-05	0.00125	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.07e-05	0.00123	CbGpPWpGaD
Sulindac—MAPK3—MyD88:Mal cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	6.05e-05	0.00123	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.98e-05	0.00122	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	5.92e-05	0.0012	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.89e-05	0.0012	CbGpPWpGaD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.88e-05	0.0012	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	5.88e-05	0.00119	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	5.87e-05	0.00119	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ACTG1—acquired immunodeficiency syndrome	5.85e-05	0.00119	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	5.83e-05	0.00118	CbGpPWpGaD
Sulindac—MAPK3—MyD88-independent cascade—IL6—acquired immunodeficiency syndrome	5.8e-05	0.00118	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—TAT—acquired immunodeficiency syndrome	5.75e-05	0.00117	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	5.74e-05	0.00117	CbGpPWpGaD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—IL6—acquired immunodeficiency syndrome	5.66e-05	0.00115	CbGpPWpGaD
Sulindac—MAPK3—Senescence-Associated Secretory Phenotype (SASP)—IL6—acquired immunodeficiency syndrome	5.53e-05	0.00112	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—TNF—acquired immunodeficiency syndrome	5.48e-05	0.00111	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.47e-05	0.00111	CbGpPWpGaD
Sulindac—MAPK3—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	5.45e-05	0.00111	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—IL6—acquired immunodeficiency syndrome	5.41e-05	0.0011	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.35e-05	0.00109	CbGpPWpGaD
Sulindac—MAPK3—Activated TLR4 signalling—IL6—acquired immunodeficiency syndrome	5.22e-05	0.00106	CbGpPWpGaD
Sulindac—SLC22A6—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	5.2e-05	0.00106	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	5.19e-05	0.00105	CbGpPWpGaD
Sulindac—MAPK3—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	5.15e-05	0.00105	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Insulin receptor—IL6—acquired immunodeficiency syndrome	5.11e-05	0.00104	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	5.1e-05	0.00104	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—CSF2—acquired immunodeficiency syndrome	5.06e-05	0.00103	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	5.04e-05	0.00102	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.93e-05	0.001	CbGpPWpGaD
Sulindac—MAPK3—Toll Like Receptor 4 (TLR4) Cascade—IL6—acquired immunodeficiency syndrome	4.91e-05	0.000997	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AGPS—acquired immunodeficiency syndrome	4.89e-05	0.000993	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IFNG—acquired immunodeficiency syndrome	4.84e-05	0.000982	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MBL2—acquired immunodeficiency syndrome	4.81e-05	0.000976	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	4.78e-05	0.000972	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	4.78e-05	0.00097	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	4.75e-05	0.000964	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	4.73e-05	0.00096	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	4.71e-05	0.000957	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	4.7e-05	0.000954	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—TAT—acquired immunodeficiency syndrome	4.56e-05	0.000927	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.56e-05	0.000927	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	4.47e-05	0.000907	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	4.47e-05	0.000907	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—IL6—acquired immunodeficiency syndrome	4.42e-05	0.000898	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	4.39e-05	0.000891	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	4.37e-05	0.000888	CbGpPWpGaD
Sulindac—MAPK3—Toll-Like Receptors Cascades—IL6—acquired immunodeficiency syndrome	4.37e-05	0.000888	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.36e-05	0.000886	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.36e-05	0.000886	CbGpPWpGaD
Sulindac—PTGS2—Disease—APOBEC3G—acquired immunodeficiency syndrome	4.36e-05	0.000885	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	4.3e-05	0.000873	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	4.25e-05	0.000863	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	4.18e-05	0.00085	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.13e-05	0.000838	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	4.12e-05	0.000836	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—TAT—acquired immunodeficiency syndrome	4.05e-05	0.000823	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.94e-05	0.000801	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	3.93e-05	0.000799	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	3.91e-05	0.000795	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	3.89e-05	0.000791	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AGPS—acquired immunodeficiency syndrome	3.88e-05	0.000788	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.88e-05	0.000788	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.88e-05	0.000788	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—IL6—acquired immunodeficiency syndrome	3.87e-05	0.000787	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	3.86e-05	0.000784	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	3.8e-05	0.000772	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	3.79e-05	0.00077	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CCR2—acquired immunodeficiency syndrome	3.77e-05	0.000766	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	3.72e-05	0.000755	CbGpPWpGaD
Sulindac—PTGS2—Disease—CCNT1—acquired immunodeficiency syndrome	3.7e-05	0.000752	CbGpPWpGaD
Sulindac—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	3.69e-05	0.00075	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	3.64e-05	0.00074	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—IL6—acquired immunodeficiency syndrome	3.64e-05	0.00074	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	3.64e-05	0.00074	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	3.61e-05	0.000734	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	3.58e-05	0.000727	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	3.56e-05	0.000724	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—IL6—acquired immunodeficiency syndrome	3.5e-05	0.000712	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	3.44e-05	0.0007	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IFNA1—acquired immunodeficiency syndrome	3.39e-05	0.000689	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—ALB—acquired immunodeficiency syndrome	3.3e-05	0.00067	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD79A—acquired immunodeficiency syndrome	3.29e-05	0.000669	CbGpPWpGaD
Sulindac—MAPK3—Disease—CXCR4—acquired immunodeficiency syndrome	3.27e-05	0.000665	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	3.23e-05	0.000656	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.16e-05	0.000642	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.15e-05	0.000639	CbGpPWpGaD
Sulindac—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	3.14e-05	0.000638	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.12e-05	0.000634	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	3.11e-05	0.000633	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	3.07e-05	0.000623	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	3e-05	0.000609	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.95e-05	0.000599	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.91e-05	0.00059	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.69e-05	0.000547	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD40LG—acquired immunodeficiency syndrome	2.69e-05	0.000546	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—IL2—acquired immunodeficiency syndrome	2.68e-05	0.000544	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.66e-05	0.00054	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD8A—acquired immunodeficiency syndrome	2.66e-05	0.000539	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CSF2—acquired immunodeficiency syndrome	2.66e-05	0.000539	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	2.65e-05	0.000538	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.64e-05	0.000537	CbGpPWpGaD
Sulindac—PPARD—Metabolism—ALB—acquired immunodeficiency syndrome	2.62e-05	0.000532	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.62e-05	0.000532	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	2.58e-05	0.000525	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-B—acquired immunodeficiency syndrome	2.55e-05	0.000519	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	2.53e-05	0.000513	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	2.53e-05	0.000513	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	2.5e-05	0.000507	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.48e-05	0.000504	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.44e-05	0.000495	CbGpPWpGaD
Sulindac—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	2.44e-05	0.000495	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.29e-05	0.000465	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.29e-05	0.000465	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.25e-05	0.000457	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—IL6—acquired immunodeficiency syndrome	2.25e-05	0.000456	CbGpPWpGaD
Sulindac—MAPK3—Disease—CCR5—acquired immunodeficiency syndrome	2.24e-05	0.000456	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	2.2e-05	0.000446	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.99e-05	0.000404	CbGpPWpGaD
Sulindac—PTGS2—Disease—CXCR4—acquired immunodeficiency syndrome	1.95e-05	0.000395	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.86e-05	0.000377	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.79e-05	0.000363	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.74e-05	0.000354	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.72e-05	0.000349	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.6e-05	0.000326	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.59e-05	0.000322	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IFNG—acquired immunodeficiency syndrome	1.58e-05	0.000321	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.57e-05	0.000319	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.54e-05	0.000312	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD4—acquired immunodeficiency syndrome	1.53e-05	0.00031	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.42e-05	0.000288	CbGpPWpGaD
Sulindac—MAPK3—Disease—CD4—acquired immunodeficiency syndrome	1.41e-05	0.000286	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL2—acquired immunodeficiency syndrome	1.4e-05	0.000285	CbGpPWpGaD
Sulindac—PTGS2—Disease—CCR5—acquired immunodeficiency syndrome	1.33e-05	0.000271	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	1.29e-05	0.000262	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.01e-05	0.000205	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ALB—acquired immunodeficiency syndrome	1e-05	0.000204	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.07e-06	0.000184	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.03e-06	0.000183	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD4—acquired immunodeficiency syndrome	8.37e-06	0.00017	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6—acquired immunodeficiency syndrome	8.25e-06	0.000168	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ALB—acquired immunodeficiency syndrome	7.96e-06	0.000162	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6—acquired immunodeficiency syndrome	7.62e-06	0.000155	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ALB—acquired immunodeficiency syndrome	7.06e-06	0.000143	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.33e-06	0.000108	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6—acquired immunodeficiency syndrome	4.53e-06	9.2e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	4.5e-06	9.15e-05	CbGpPWpGaD
